The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with ...

Panelists discuss how successful access initiatives include integrated specialty pharmacies, community-based clinics, clinical trial opportunities, telehealth services, and financial assistance ...

Trial investigator Emma Guttman, MD, PhD, chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, here explains why targeting the OX40-OX40 ligand pathway is so exciting ...

Perioral dermatitis is a skin condition that can make you feel frustrated and confused at the same time, causing red bumps, ...

We spoke to dermatologists and conducted research to pick the best lotions for eczema, including picks from brands like ...

It can be hard to feel good about your skin care routine when so many products come in plastic and you’re constantly pushed ...

Greater baseline EASI scores and greater BMI are associated with poor response to lebrikizumab among patients with moderate to severe AD.

A Wound That Shouldn’t Exist Few injuries are as shocking to discover as a deep, infected sore on the body of a loved one in ...

Discover a study proposing a unified European paediatric baseline series to improve patch testing and diagnosis of childhood contact dermatitis.

Topical ruxolitinib does not carry the same safety profile as oral JAK inhibitors for AD, which may warrant reconsideration of the boxed warning.

In this EMJ webinar, Thomas Luger joins moderator Sue Saville to explore the latest evidence and practical guidance for managing mild ...

Les Masterson is a deputy editor and insurance analyst at Forbes Advisor. He has been a journalist, reporter, editor and content creator for more than 25 years. He has covered insurance for a decade, ...